الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 116 |  |  |
| | | from | 116 | | |
Abstract
Differentiated thyroid cancer (DTC) is currently one of the fastest rising cancer diagnoses in the world. DTC has an excellent prognosis with appropriate treatment. Total thyroidectomy is the treatment of choice for patients with DTC, and thyroidectomy should be followed by 131I ablation to remove any remnant thyroid tissue.
The extent of remnant thyroid tissue is one of the most important factors that help to guide RAIT and influence the outcome of ablation. Several diagnostic procedures to assess the remnant, one of them commonly used nowadays is 99mTc pertechnetate scintigraphy.
We aimed in this study to estimate the role of 99mTc pertechnetate scintigraphy and 99mTc SestaMIBI scintigraphy to ablation outcome primarily, then to assess the potential role of those WBSs in assessment of extra-thyroidal lesions in whom patients. This prospective study included 31 post- operative non metastatic patients referred to our unit for RAIT. 99mTc pertechnetate WBS then on separate day 99mTc SestaMIBI scintigraphy was performed.
We found that 99mTc SestaMIBI can predict 74% of patients with unsuccessful ablation, even it is statistically in significant, and also 99mTc pertechnetate scintigraphy can predict 67% of unablated patients.
99mTc pertechnetate WBS can identify metastatic lesions in DTC patients in 3 cases mainly bone and lung metastases.
99mTc SestaMIBI scintigraphy can detect 87% (7/8) of post-operative metastatic DTC patients. In comparison the later to 99mTc pertechnetate WBS it is slightly sensitive in assessment of extra-thyroidal lesions.
There is statistically significant association between 99mTc pertechnetae scintigraphy results and Tg level, however there’s no statistically significant association between it and 99mTc SestaMIBI results in our study.